Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
HILS

HILS - Hillstream BioPharma, Inc. Stock Price, Fair Value and News

1816.00USD-12.00 (-0.66%)Delayed
Watchlist

Market Summary

USD1816.00-12.00
Delayed
-0.66%

HILS Stock Price

View Fullscreen

HILS RSI Chart

HILS Valuation

Market Cap

22.4B

Price/Earnings (Trailing)

-2.4K

Price/Sales (Trailing)

146.8K

Price/Free Cashflow

-3.1K

HILS Price/Sales (Trailing)

HILS Profitability

Return on Equity

-102.06%

Return on Assets

-85.13%

Free Cashflow Yield

-0.03%

HILS Fundamentals

HILS Revenue

Revenue (TTM)

152.6K

Rev. Growth (Qtr)

102.92%

HILS Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

-40.04%

Earnings Growth (Qtr)

-35.91%

Breaking Down HILS Revenue

Last 7 days

-4.8%

Last 30 days

-0.8%

Last 90 days

9.8%

Trailing 12 Months

465779.9%

How does HILS drawdown profile look like?

HILS Financial Health

Current Ratio

6.03

HILS Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-7.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023000152.6K
20220000

Tracking the Latest Insider Buys and Sells of Hillstream BioPharma, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 14, 2022
appajosyula sireesh
gifted
-
-
-75,757
-
Jul 14, 2022
appajosyula sireesh
gifted
-
-
7,576
-
Jun 17, 2022
milby randy
bought
389
0.7799
500
chief executive officer
Jun 06, 2022
milby randy
bought
688
0.688463
1,000
chief executive officer
Jun 01, 2022
milby randy
bought
0.94
0.94
1.00
chief executive officer
May 25, 2022
milby randy
bought
786
0.786
1,000
chief executive officer
May 20, 2022
milby randy
bought
918
0.91825
1,000
chief executive officer
May 19, 2022
milby randy
bought
907
0.90765
1,000
chief executive officer
Apr 18, 2022
milby randy
acquired
24,341
0.101203
240,526
chief executive officer
Jan 14, 2022
milby randy
acquired
884,125
3.2
276,289
chief executive officer

1–10 of 14

Which funds bought or sold HILS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
10,041
10,041
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-11,414
-
-%
Feb 14, 2024
STATE STREET CORP
sold off
-100
-5,154
-
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
sold off
-100
-7,549
-
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
new
-
688
688
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-3,813
-
-%
Feb 09, 2024
UBS Group AG
sold off
-100
-8,766
-
-%
Feb 09, 2024
WELLS FARGO & COMPANY/MN
new
-
3.00
3.00
-%
Feb 09, 2024
WELLS FARGO & COMPANY/MN
sold off
-100
-15.00
-
-%
Feb 07, 2024
Warberg Asset Management LLC
new
-
5,091
5,091
-%

1–10 of 14

Are Funds Buying or Selling HILS?

Are funds buying HILS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HILS
No. of Funds

Unveiling Hillstream BioPharma, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
tang capital partners lp
0.0%
0
SC 13G/A
Dec 07, 2023
tang capital partners lp
9.99%
252,549
SC 13G

Recent SEC filings of Hillstream BioPharma, Inc.

View All Filings
Date Filed Form Type Document
Feb 23, 2024
10-K
Annual Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
8-K
Current Report
Dec 18, 2023
4
Insider Trading
Dec 12, 2023
8-K
Current Report
Dec 11, 2023
8-K/A
Current Report
Dec 08, 2023
8-K
Current Report
Dec 07, 2023
8-K
Current Report
Dec 07, 2023
SC 13G
Major Ownership Report
Dec 04, 2023
4
Insider Trading

Peers (Alternatives to Hillstream BioPharma, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.9B
1.8B
-23.99% -31.71%
-45.13
10.87
76.23% 61.08%
17.2B
2.3B
-4.89% -18.90%
116.89
7.44
15.05% 75.21%
13.6B
3.7B
-7.62% -26.87%
22.76
3.68
8.87% 75.42%
MID-CAP
8.1B
272.9M
-2.06% 34.31%
-13.39
29.73
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.34
6.44
23.54% 31.53%
3.9B
240.7M
-19.08% -10.99%
-13.19
16.26
-1.03% -92.09%
3.7B
270.6M
8.92% 47.81%
-15.63
13.82
440.80% -27.84%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.15
4.3
81.69% -7.29%
629.6M
1.0B
-9.17% -57.89%
-1.15
0.6
-43.15% 58.48%
179.0M
4.9M
-14.18% -58.18%
-1.09
36.62
-57.57% 50.48%
114.7M
881.7K
289.54% 381.25%
-2.42
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Hillstream BioPharma, Inc. News

Latest updates
InvestorPlace5 months ago

Hillstream BioPharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q4
Revenue102.9%58.0028.0034.0032.00-
Operating Expenses37.2%2,5311,8452,3652,7141,766
  S&GA Expenses13.4%1,5381,3571,3341,6671,083
  R&D Expenses103.4%9934881,0311,048683
Interest Expenses-89.9%354*3.007.006.00-
Net Income-35.9%-2,473-1,820-2,336-2,688-1,766
Net Income Margin-Infinity%-61.06*----
Free Cashflow-55.6%-1,400-900-1,535-3,464-892
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets245.6%10,9463,1674,5994,7226,6898,01810,24812,091622----
  Current Assets245.6%10,9463,1674,5994,7226,6898,01810,24812,091622---295
    Cash Equivalents306.7%10,9352,6893,9043,5696,5117,5979,48411,1224.00---192
Liabilities28.7%1,8151,4101,5301,5211,1459021,2081,7525,3074,9834,6594,3364,012
  Current Liabilities28.7%1,8151,4101,5301,5211,1459021,2081,7524,534---2,725
Shareholder's Equity419.7%9,1311,7573,0693,2015,5447,1169,04010,3392,2262,2192,2151,661986
  Retained Earnings-11.1%-24,703-22,229-20,400-18,100-15,384-13,617-11,490-9,853-6,911----4,704
  Additional Paid-In Capital40.9%33,90424,05523,54721,34220,99720,79520,55420,1912,226---986
Shares Outstanding-33.0%11,74017,51216,81411,51411,51411,24811,57311,3646,3576,3576,3576,3576,357
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations-55.6%-1,400-900-1,535-3,464-892-1,548-1,388-2,728-7.67-316-269-492-
  Share Based Compensation7.9%17015815834520224133919.007.004.00554674-
Cashflow From Financing3257.4%9,662-3061,846523-193-338-26413,860-33.06333276323-

HILS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 488,177$ 831,844$ 2,566,910$ 1,595,219
General and administrative1,356,8931,295,6424,357,1543,520,281
Total operating expenses1,845,0702,127,4866,924,0645,115,500
Loss from operations(1,845,070)(2,127,486)(6,924,064)(5,115,500)
Other income (expense)    
Interest expense(3,496)(16,151)(1,591,244)
Interest income28,45194,898
Total other income (expense), net24,95578,747(1,591,244)
Net loss$ (1,820,115)$ (2,127,486)$ (6,845,317)$ (6,706,744)
Net loss per share:    
Basic$ (0.11)$ (0.18)$ (0.47)$ (0.60)
Diluted$ (0.11)$ (0.18)$ (0.47)$ (0.60)
Weighted average number of common shares outstanding:    
Basic17,294,11311,531,89914,607,39411,248,041
Diluted17,294,11311,531,89914,607,39411,248,041

HILS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash$ 2,689,061$ 6,510,534
Prepaid expenses and other current assets412,890178,094
Deferred offering costs65,000
Total current assets3,166,9516,688,628
Total assets3,166,9516,688,628
Current liabilities  
Accounts payable1,138,695954,505
Accrued expenses190,293190,468
Insurance premium financing liability81,040
Total current liabilities1,410,0281,144,973
Total liabilities1,410,0281,144,973
Commitments and contingencies (see Note 8)
Stockholders’ equity  
Preferred stock, $0.0001 par value, 10,000,000 shares  authorized, no shares issued and outstanding as of September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 250,000,000 shares authorized, 17,602,665 shares and 11,604,970 shares issued and 17,511,839 shares and 11,514,144 shares outstanding  as of September 30, 2023 and December 31, 2022, respectively1,7601,160
Additional paid-in capital24,054,87720,996,892
Accumulated deficit(22,229,749)(15,384,432)
Treasury stock, at cost, 90,826 shares held in treasury  as of September 30, 2023 and December 31, 2022(69,965)(69,965)
Total stockholders’ equity1,756,9235,543,655
Total liabilities and stockholders’ equity$ 3,166,951$ 6,688,628
HILS
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
 CEO
 WEBSITEwww.hillstreambio.com
 EMPLOYEES1

Hillstream BioPharma, Inc. Frequently Asked Questions


What is the ticker symbol for Hillstream BioPharma, Inc.? What does HILS stand for in stocks?

HILS is the stock ticker symbol of Hillstream BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hillstream BioPharma, Inc. (HILS)?

As of Mon Jan 08 2024, market cap of Hillstream BioPharma, Inc. is 22.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HILS stock?

You can check HILS's fair value in chart for subscribers.

What is the fair value of HILS stock?

You can check HILS's fair value in chart for subscribers. The fair value of Hillstream BioPharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hillstream BioPharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HILS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hillstream BioPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether HILS is over valued or under valued. Whether Hillstream BioPharma, Inc. is cheap or expensive depends on the assumptions which impact Hillstream BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HILS.

What is Hillstream BioPharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jan 08 2024, HILS's PE ratio (Price to Earnings) is -2403.59 and Price to Sales (PS) ratio is 146.75 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HILS PE ratio will change depending on the future growth rate expectations of investors.